Cialis and Sildenafil Interaction: What Happens When You Combine Two PDE5 Inhibitors

The Short Answer: No, You Cannot Safely Combine Tadalafil and Sildenafil

Combining tadalafil and sildenafil is pharmacologically irrational and clinically dangerous. Both molecules occupy the same catalytic binding pocket on PDE5, meaning you get overlapping, not complementary, effects, with all of the vasodilatory risk and none of the therapeutic benefit. The FDA prescribing information for tadalafil states that use with other PDE5 inhibitors has not been studied and is not recommended [1].

Why Patients Ask About This Combination

The question surfaces for two reasons. First, some patients take daily low-dose tadalafil (2.5 mg or 5 mg) for benign prostatic hyperplasia or erectile dysfunction and wonder whether adding an as-needed sildenafil dose could produce a stronger erection on demand. Second, some patients have prescriptions from different providers who are unaware of the other medication. Neither scenario justifies concurrent use.

What the FDA Labels Actually Say

The FDA-approved prescribing information for tadalafil (Adcirca/Cialis) explicitly states: "The use of tadalafil with other PDE5 inhibitors (such as sildenafil) has not been studied and is not recommended." [1] The sildenafil (Viagra) label carries an equivalent warning [2]. These are not precautionary soft warnings, they reflect a recognized pharmacodynamic interaction with life-threatening potential.

Mechanism: How Tadalafil and Sildenafil Interact at the Molecular Level

PDE5 Inhibition and cGMP Accumulation

Both drugs work by blocking phosphodiesterase type 5, the enzyme that degrades cyclic guanosine monophosphate (cGMP) in vascular smooth muscle. Nitric oxide from endothelial cells activates guanylate cyclase, raising cGMP, which relaxes smooth muscle and dilates blood vessels. PDE5 normally terminates this signal. When you block PDE5, cGMP accumulates and vasodilation is prolonged [3].

Sildenafil achieves roughly 80% PDE5 inhibition at its 100 mg therapeutic dose [4]. Tadalafil at 20 mg produces similar PDE5 occupancy, although its longer half-life means enzyme blockade persists for up to 36 hours [5]. Adding both drugs does not produce 160% inhibition, PDE5 enzyme sites are finite, but it does prolong and deepen cGMP-mediated vasodilation beyond what either drug achieves alone, with unpredictable magnitude.

Pharmacokinetic Overlap

Sildenafil is primarily metabolized by CYP3A4 and secondarily by CYP2C9, producing an active metabolite (N-desmethylsildenafil) with roughly 50% of the potency of the parent compound [2]. Tadalafil is also a CYP3A4 substrate, metabolized to inactive catechol glucuronide [1]. Co-administration does not produce a classic CYP-mediated pharmacokinetic interaction where one drug raises the plasma level of the other, the concern is entirely pharmacodynamic (additive effect on the same target), not pharmacokinetic (altered plasma concentrations) [6].

Systemic Hemodynamic Consequences

In a well-characterized single-drug study published in the European Journal of Clinical Pharmacology, sildenafil 100 mg lowered supine systolic blood pressure by a mean of 8.4 mmHg and diastolic by 5.5 mmHg in healthy volunteers [7]. Tadalafil 20 mg produced comparable reductions: mean decreases of 1.6 mmHg systolic and 0.8 mmHg diastolic in one crossover study, with outlier drops exceeding 20 mmHg in some participants [5]. The additive scenario of two drugs simultaneously occupying PDE5 across pulmonary and systemic vasculature has no safety data and carries the theoretical risk of syncope, reflex tachycardia, and end-organ hypoperfusion.

Severity Classification and DDI Database Ratings

Clinical Pharmacology and Lexicomp Ratings

Major drug interaction databases rate the tadalafil-sildenafil combination as "contraindicated" or "major." Lexicomp assigns a "D" rating (consider therapy modification), while Clinical Pharmacology rates the interaction as a "Contraindicated Combination" based on pharmacodynamic additivity [8]. The Micromedex severity index lists this as "contraindicated" with a "major" severity modifier and "probable" documentation level [9].

How This Compares to Other PDE5 Inhibitor Interactions

The nitrate-PDE5 inhibitor interaction is the more famous contraindication. Organic nitrates (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) donate nitric oxide directly, producing a pharmacodynamic interaction with PDE5 inhibitors that can drop systolic blood pressure below 85 mmHg [1][2]. The PDE5 inhibitor-plus-PDE5 inhibitor interaction is mechanistically similar: two drugs amplifying the same downstream pathway. Both are hard contraindications, not dose-adjustment situations.

Populations at Highest Risk

Cardiovascular Disease

Patients with baseline cardiac disease, heart failure, or autonomic neuropathy are particularly vulnerable to blood pressure drops from PDE5 inhibitor combinations. The Princeton Consensus Panel guidelines, a set of expert recommendations on sexual activity in cardiovascular disease, stratify patients by cardiac risk before prescribing any PDE5 inhibitor [10]. Adding a second PDE5 inhibitor moves any patient, regardless of starting risk tier, into the high-risk category.

Alpha-Blocker Users

Both tadalafil and sildenafil interact with alpha-1 adrenergic blockers (tamsulosin, doxazosin, prazosin) to produce additive hypotension [1][2]. Patients on alpha-blockers for BPH who are prescribed daily tadalafil and then add sildenafil face a three-way vasodilatory interaction with no studied safety floor. A 2004 study in the Journal of Urology demonstrated that sildenafil combined with doxazosin produced symptomatic hypotension in 6 of 24 healthy volunteers [11]. Stacking tadalafil on top removes the already-thin safety margin.

Older Adults and Polypharmacy

Men over 65 metabolize both drugs more slowly. The half-life of tadalafil is prolonged in this group, with AUC values roughly 25% higher in subjects over 65 compared to younger men [1]. Sildenafil clearance is similarly reduced, with AUC approximately 90% higher in men over 65 compared to young healthy men at equivalent doses [2]. The pharmacokinetic overlap window is therefore wider in older patients, increasing exposure duration for both drugs simultaneously.

Washout Periods: How Long Must You Wait Between Drugs

The minimum safe washout is five half-lives of the first drug. Here is how to apply that rule clinically:

Switching from tadalafil to sildenafil:

Tadalafil's mean half-life is 17.5 hours. Five half-lives equals approximately 87.5 hours (roughly 3.6 days). In practice, clinicians should wait at least 4 full days after the last tadalafil dose before administering sildenafil. For patients on daily 5 mg tadalafil, the steady-state washout may require closer to 5 days given accumulation.

Switching from sildenafil to tadalafil:

Sildenafil's half-life is 3 to 5 hours; its active metabolite N-desmethylsildenafil has a similar half-life [2]. Five half-lives of sildenafil plus metabolite clears in roughly 24 to 25 hours. Waiting 24 hours after the last sildenafil dose before initiating tadalafil is a conservative minimum, with 48 hours providing additional margin in older patients or those with hepatic impairment [12].

Daily vs. As-needed dosing

Daily tadalafil creates a persistent plasma concentration plateau. A patient taking 5 mg daily for 7 days has a steady-state Cmax and prolonged trough that differs substantially from a single 20 mg on-demand dose. Switching from daily tadalafil requires the full 4 to 5 day washout regardless of perceived mild symptom control.

Patient Counseling Points

What to Tell Patients Who Are Already Taking Both

If a patient discloses concurrent use, the immediate priority is stopping one drug, not adjusting doses of either. There is no established "safe low dose" for dual PDE5 inhibitor therapy in erectile dysfunction. The American Urological Association (AUA) guidelines on erectile dysfunction state that PDE5 inhibitors should be prescribed as monotherapy and that switching between agents requires full washout [13].

Clinicians should screen for nitrate use at the same time. A patient inadvertently on tadalafil, sildenafil, and sublingual nitroglycerin PRN faces a compounded contraindication. That scenario requires immediate medication reconciliation.

Explaining Risk in Plain Terms

Blood pressure can drop fast. Dizziness within minutes of taking either drug alone is possible; dizziness, fainting, or in rare cases loss of consciousness becomes more likely when both are on board. Patients should know that taking "just half a sildenafil" on top of their daily tadalafil does not eliminate the risk. The vasodilatory mechanism is active at sub-therapeutic doses of both drugs [4][7].

Documentation and Prescriber Communication

Any patient presenting with a prescription for one PDE5 inhibitor who mentions another should trigger an immediate prescriber-to-prescriber check. Electronic prescribing systems with formulary-level interaction checking flag this combination as contraindicated in most major pharmacy software platforms. Patients should carry a medication list and present it to every provider, including dentists prescribing nitrate-containing agents.

What to Use Instead: Evidence-Based Monotherapy Options

Choosing Between Tadalafil and Sildenafil

For erectile dysfunction, both drugs carry Class I recommendations in the AUA ED guidelines [13]. The choice depends on sexual frequency and patient preference:

• Tadalafil 5 mg daily is preferred for men having intercourse more than twice per week or for those who want spontaneity, given its 36-hour window [1].
• Sildenafil 50 mg as needed (titrated to 25 mg or 100 mg) is preferred for men with infrequent intercourse who want on-demand dosing [2].
• Vardenafil 10 mg and avanafil 100 mg are alternatives within the same class; switching to one of these from the other replaces, does not supplement, the original agent [14][15].

Combination Therapy for BPH: The Right Kind

In BPH, the evidence-based combination is tadalafil 5 mg daily plus an alpha-blocker or a 5-alpha reductase inhibitor, not two PDE5 inhibitors. The MTOPS trial (N=3,047) demonstrated that combined finasteride plus doxazosin reduced BPH symptom progression significantly more than either agent alone, without requiring dual PDE5 blockade [16]. Tadalafil 5 mg is approved as monotherapy for BPH; it is not approved or indicated as part of a dual-PDE5 regimen.

When Neither Drug Works Alone

If a patient has failed adequate trials of both tadalafil and sildenafil at maximum doses, 20 mg tadalafil on demand or 5 mg daily tadalafil for at least 8 weeks, and 100 mg sildenafil on demand for at least 6 attempts, the next step is not combining them. The AUA recommends evaluation for organic causes (vascular, neurogenic, hormonal), penile injection therapy with alprostadil, vacuum erection devices, or surgical consultation for penile prosthesis implantation [13].

Drug Interactions Beyond the PDE5 Class: Full Tadalafil Interaction Profile

CYP3A4 Inhibitors

Strong CYP3A4 inhibitors raise tadalafil plasma exposure significantly. Ketoconazole 400 mg daily increased tadalafil AUC by 312% in a controlled pharmacokinetic study [1]. Ritonavir 200 mg twice daily raised tadalafil AUC by 124% [1]. For patients on strong CYP3A4 inhibitors, the tadalafil dose should not exceed 10 mg in 72 hours for on-demand use, per FDA label guidance [1].

Nitrates

Tadalafil is absolutely contraindicated with all organic nitrates, including short-acting nitroglycerin taken as needed. This contraindication has no time window, even a single dose of nitroglycerin within 48 hours of tadalafil can produce severe hypotension [1]. The ACC/AHA guidelines on nitrate therapy in stable ischemic heart disease specifically address this contraindication and recommend that patients on tadalafil not be given nitrates for angina [17].

Antihypertensives and Alcohol

Tadalafil 20 mg combined with amlodipine 5 mg produced mean additional blood pressure reductions of 8 mmHg systolic and 7 mmHg diastolic in one open-label pharmacodynamic study [1]. Alcohol at 0.7 g/kg increased the rate of postural hypotension with tadalafil but did not significantly change mean blood pressure in the key PK interaction study [1]. Both interactions are additive and dose-dependent [5][18].

Antifungals and Macrolide Antibiotics

Erythromycin, a moderate CYP3A4 inhibitor, raised tadalafil AUC by approximately 182% in one PK study [1]. Patients starting a macrolide antibiotic course while on daily tadalafil may experience enhanced vasodilatory effects within 1 to 2 days. Dose reduction or temporary pause of tadalafil should be considered by the prescribing clinician in this scenario [12].

Sildenafil's Full Interaction Profile for Completeness

CYP3A4 and CYP2C9 Substrates

Sildenafil is metabolized by both CYP3A4 (primary) and CYP2C9 (minor). Cimetidine 800 mg, a non-specific CYP inhibitor, raised sildenafil AUC by 56% [2]. Erythromycin raised sildenafil AUC by 182% [2]. Saquinavir, a protease inhibitor and CYP3A4 inhibitor, raised sildenafil AUC by 210% [2]. The FDA label recommends a maximum 25 mg sildenafil dose in 48 hours for patients on ritonavir [2].

Guanylate Cyclase Stimulators

Riociguat (Adempas), a soluble guanylate cyclase stimulator used in pulmonary arterial hypertension, is contraindicated with all PDE5 inhibitors, including sildenafil [19]. The mechanism parallels the PDE5-plus-PDE5 interaction: both riociguat and PDE5 inhibitors raise cGMP through different routes, producing additive vasodilation. This contraindication is listed in both the riociguat and sildenafil FDA labels [2][19].

Clinical Monitoring if Inadvertent Co-Exposure Occurs

If a patient has taken both drugs within the same elimination window, monitoring should include:

• Blood pressure checked at rest and after standing for 2 minutes (orthostatic assessment)
• Heart rate measurement, reflex tachycardia above 100 bpm suggests hemodynamic stress
• Inquiry about symptoms: lightheadedness, visual changes, chest discomfort, flushing
• If symptomatic hypotension is present (systolic <90 mmHg or drop >20 mmHg on standing), the patient should be placed supine with legs elevated and IV access established if available

Asymptomatic patients who took both drugs but have normal orthostatic blood pressure and heart rate may be observed for 4 to 6 hours given sildenafil's shorter half-life. Symptomatic patients warrant emergency evaluation [20].

A 2011 case report in the American Journal of Emergency Medicine documented a 58-year-old man who took sildenafil 100 mg approximately 6 hours after his last 20 mg tadalafil dose and presented with a systolic blood pressure of 74 mmHg, resolved with IV fluid resuscitation and supine positioning over 3 hours [20]. This case illustrates the clinical reality of what is a theoretical pharmacodynamic interaction in most database summaries.